The combination of immune checkpoint inhibitors (ICIs) and radiotherapy (RT) improves outcomes in non-small cell lung cancer (NSCLC). However, the potential abscopal effect of RT for bone metastases (BoMs) remains unclear. The present retrospective study aimed to evaluate the impact of RT for BoMs on lung lesion response and survival in patients with NSCLC receiving ICIs. A total of 108 patients with NSCLC with BoMs treated with ICIs between March 2016 and January 2024 were included and divided into two groups based on whether they received RT for BoMs. Primary outcomes included the lung lesion response rate, overall survival (OS), progression-free survival (PFS) and incidence of immune-related adverse events (irAEs). Among 33 patients who received RT for BoM (RT-BoM group), the dose/fraction ranged from 2 to 8 Gy/1 to15 fx (total 8-39 Gy). The lung lesion response rate was significantly higher in the RT-BoM group than in the non-RT-BoM group (n=75; 42.4 vs. 21.3%; P=0.03). The median OS and PFS times were significantly longer in the RT-BoM group (24.9 vs. 16.3 months, P=0.01; 11.0 months vs. 6.2 months, P=0.03), while the incidence of irAEs was comparable (21.2 vs. 21.3%; P=0.99). The group that received RT before ICI initiation (n=22) had a significantly higher lung lesion response rate than the group that received RT after ICI initiation (n=11; 54.5 vs. 9.1%; P=0.02), with a trend toward prolonged OS and PFS. Multivariate analysis identified RT for BoMs as an independent predictor of lung response (P=0.02), OS (P=0.03) and PFS (P=0.02). RT for BoMs was associated with improved lung response and prognosis in patients with NSCLC receiving ICIs, suggesting a possible abscopal effect. Further validation in prospective studies with larger patient groups is warranted.
NSCLCBoMICIRTabscopal effectFunding: No funding was received.Introduction
Recent advances in immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have significantly improved treatment outcomes in non-small cell lung cancer (NSCLC), with improvements in overall survival (OS) and progression-free survival (PFS) (1–6). ICIs can yield favorable clinical outcomes even in patients with NSCLC and bone metastases (BoMs) (7–11), a condition traditionally associated with poor prognosis (12–14). However, not all patients respond favorably, highlighting a need for continued research to enhance the therapeutic efficacy of ICIs.
In our clinical experience, we have observed several cases of NSCLC with BoMs where bone-targeted radiotherapy (RT) combined with ICIs achieved lung tumor shrinkage and prolonged survival. This phenomenon, where tumors shrink at sites distant from the irradiated area, is known as the abscopal effect (15). RT promotes an antitumor immune response by inducing antigen release and immunogenic cell death, enhancing maturation and antigen presentation by antigen-presenting cells, mobilizing T cells, and sensitizing tumor cells to immune-mediated cell death, which may underlie the abscopal effect (15,16). Although the abscopal effect is rare and its mechanisms are unclear (17), ICIs may enhance immune responses induced by RT, suggesting a potential synergistic effect that could improve ICI efficacy (16–20). Notably, increased infiltration and enhanced cytotoxic function of CD8+ T cells within the tumor immune microenvironment have been reported to play a crucial role in augmenting the abscopal effect (21,22). However, the relationship between RT for BoMs and the abscopal effect in ICI-treated NSCLC has not been elucidated. The study aimed to determine whether RT for BoMs induces an abscopal effect in ICI-treated NSCLC and the clinical benefits of this effect.
Patients and methodsStudy design and patient population
This retrospective study included patients with advanced NSCLC diagnosed with BoMs before receiving ICI treatment between January 2016 and March 2024 at Kanazawa University Hospital. The ICIs used in this study were PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab and durvalumab). For patients with negative driver-gene mutations and a PD-L1 tumor proportion score (TPS) >50%, first-line treatment was PD-1/PD-L1 inhibitor monotherapy or combination therapy with platinum-based agents. In other cases, ICIs were employed as second-line or later therapy following failure of conventional chemotherapy or molecular-targeted treatments. To accurately evaluate the effects of RT on BoMs, patients who had received RT for lung lesions or brain metastases, as well as those who had been treated with bone-modifying agents for BoMs, were excluded. Additionally, patients with a performance status of 3 or higher and those who received combination therapy with PD-1/PD-L1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors were excluded. This study was approved by the Medical Ethics Committee of Kanazawa University (approval number: 3339-1) and was conducted in accordance with relevant laws and institutional guidelines as well as with the tenets enunciated in the Declaration of Helsinki. Written informed consent was waived due to the retrospective design. Instead, consent was obtained via an opt-out method approved by the ethics committee, with study information provided publicly to allow patients to decline participation.
Data analysis
The medical records used in this study were collected from the Kanazawa University Hospital database. Data included patient characteristics such as age, sex, histological type, Eastern Cooperative Oncology Group performance status, PD-L1 TPS, number of BoM, visceral metastasis, and ICI and RT history, including timing and site of BoM. All data were reviewed independently by at least two investigators to ensure accuracy and consistency. Patients who received RT to treat multiple bone lesions were excluded to evaluate the therapeutic effect of radiation on a single metastatic bone lesion. Participants were divided into two groups: irradiated (RT-BoM) and non-irradiated BoMs (non-RT-BoM), and clinical outcomes were evaluated by assessing responses in lung lesions, OS, PFS, and the incidence of immune-related adverse events (irAEs, grade ≥3 based on Common Terminology Criteria for Adverse Events version 5.0). To evaluate local control of BoMs with and without irradiation, spinal paralysis and pathological fractures during ICI treatment were assessed. Lung lesion response was assessed based on Response Evaluation Criteria in Solid Tumors version 1.1, with size changes measured via computed tomography between ICI initiation and the final follow-up. This radiological evaluation was performed by at least two physicians, including radiologists, to ensure accuracy and reliability.
Statistical analysis
OS and PFS from ICI treatment initiation were assessed using the Kaplan-Meier curve analysis. All clinical data were used as variables, with Fisher's exact and log-rank tests to compare between the two groups. In addition, logistic regression and the COX proportional hazards models were used in multivariate analysis to assess correlations between clinical data and outcomes and identify independent predictive factors. Cases with missing data for key variables or primary outcomes were excluded from the analysis. However, PD-L1 TPS was not assessed in some patients; these cases were included in the analysis as a separate unknown category. A P-value <0.05 was considered significant, and EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) was used for all statistical analyses.
ResultsClinical characteristics
In total, 108 patients with NSCLC having BoMs were enrolled, and their clinical characteristics are summarized in Table I. This study included 80 men and 28 women, with a mean age of 66.6±8.6 years. The median follow-up time from initiation of ICI treatment was 21.8 (2–101) months. The RT-BoM and non-RT-BoM groups included 33 and 75 patients, respectively, with no significant difference observed for clinical characteristics (Table I). In the RT-BoM group, the dose/fraction was 2-8 Gy/1-15 fx (total dose 8-39 Gy) and the most frequently irradiated site was the spine. Additionally, 66.7% of cases received radiation before initiating ICI (Table I).
Clinical outcomes between RT-BoM vs. non-RT-BoM groups
The overall response rate of lung lesions in the RT-BoM group was 42.4%, which was significantly better than that in the non-RT-BoM group (21.3%, P=0.03). The median OS and PFS in the RT-BoM group were 24.9 (17.6-NA) and 11.0 (4.9-29.6) months, respectively, significantly longer than those in the non-RT-BoM group [16.3 (11.6-20.4) months, P=0.01; 6.2 (4.4-9.8) months, P=0.03] (Fig. 1A and B). The incidence of irAEs in the RT-BoM group was 21.2%, similar to that in the non-RT-BoM group (21.3%), with no significant difference (P=0.99). No skeletal-related events (SREs) were observed after radiation in the RT-BoM group; however, two cases of pathological fracture were observed in the non-RT-BoM group during ICI treatment (both cases required surgery for vertebral pathological fractures and paralysis).
Furthermore, subgroup analyses were performed for the RT-BoM group. The group that received radiation before ICI initiation (n=22) had a significantly better lung lesion response rate than the group that received radiation after ICI initiation (n=11) (54.5 vs. 9.1%, P=0.02). Although no significant difference was observed in OS [24.9 (18.9-NA) vs. 21.0 (3.3-NA)months, P=0.58] or PFS [18.2 (5.1-NA) vs. 6.4 (1.4-64.9) months, P=0.45] between the two groups, a trend toward prolonged OS and PFS was noted in the group that received radiation before initiating ICIs. Irradiation sites of BoM were analyzed in the spine (n=22) and pelvis (n=11), where case numbers were high. No significant differences were observed between lung lesion response (22.7 vs. 36.3%, P=0.61), OS [24.8 (8.6-NA) vs. 22.6 (8.6-NA) months, P=0.44), and PFS [8.9 (3.6-NA) vs. 18.1 (4.8-NA) months, P=0.27]. However, due to the limited number of cases in each group, these findings should be interpreted with caution.
Predictive factors of clinical outcomes
Univariate analysis identified predictors of lung lesion response, revealing significant differences in sex [odds ratio and 95% confidence interval: 0.23 (0.06-0.85), P=0.02] and radiation for BoM (2.72 (1.12-6.58), P=0.01]. Multivariate analysis incorporating these factors revealed that radiation for BoM was an independent predictor [3.69 (1.20-11.40), P=0.02] (Table II). Univariate analysis for OS predictors showed significant differences in visceral metastasis [hazard ratio and 95% confidence interval: 2.72 (1.12-6.58), P=0.02] and radiation for BoM [2.21 (1.22-3.97), P<0.01]. Multivariate analysis confirmed radiation for BoM as an independent predictor of OS [2.22 (1.23-4.01), P<0.01] (Table III). For PFS, univariate analysis showed significant differences in sex [1.68 (1.05-2.70), P=0.03], treatment line of ICIs [1.73 (1.12-2.67), P=0.01], and radiation for BoM [0.60 (0.36-0.97), P=0.04]. Multivariate analysis incorporating these factors revealed that treatment line of ICIs (1.84 [1.16-2.91], P=0.01) and radiation for BoM (0.56 [0.33-0.93], P=0.02) were independent predictors of PFS (Table IV).
Discussion
Our study found that combined therapy with ICIs and RT for BoM in advanced NSCLC may induce a favorable response in lung lesions, considered an abscopal effect, and prolong prognosis, in addition to providing good local control of BoMs.
Recent, large-scale studies on immunotherapy combining ICIs and RT (23–32) have demonstrated that ICI treatment enhances the immune response induced by RT, whereas RT enhances the therapeutic effect of ICIs, confirming the existence of the abscopal effect (18–20). Several systematic reviews and meta-analyses have reported the occurrence of the abscopal effect at distant sites, alongside prolonged OS and PFS with the combination of ICIs and RT (20,33–36). However, the abscopal effect remains rare, and its underlying mechanism is not yet fully understood (17). Additionally, the relationship between irradiation of BoMs and abscopal effect in NSCLC has rarely been studied.
BoM is a poor prognostic factor in lung cancer (12–14), and SREs, such as severe pain, pathological fracture, and spinal cord compression, significantly reduces daily activity and quality of life (37,38). Therefore, early management of BoMs is crucial to prevent SREs. Generally, RT and bone-modifying agents are commonly used in combination to avoid interfering with systemic therapy (39–41). This study focused on RT for BoMs and explored its potential to improve ICI treatment efficacy. This favorable treatment effect, which can be considered an abscopal effect, may improve clinical outcomes for patients with NSCLC presenting BoMs, who typically have a poor prognosis.
Our study found that irradiation of BoMs improved the response rate of lung lesions and prolonged prognosis, consistent with reports of the abscopal effect induced by RT of lung or brain lesions (20,33–36), as well as recent findings by Facilissimo et al (42) demonstrating similar benefits of RT to BoMs in NSCLC patients receiving ICIs. In addition, no spinal paralysis and pathological fractures occurred at the irradiated site, and good local control was achieved. The incidence of grade 3 or higher irAEs, evaluated as a safety measure, was similar between the RT-BoM and non-RT-BoM groups and consistent with previous studies (36,43,44). Subgroup analysis for investigating optimal RT strategy suggested that RT prior to ICI treatment may result in better clinical outcomes. Our results aligned with the suggestion that the optimal timing for RT is either concomitant with or prior to ICI administration (19,45). Based on these results, irradiated BoMs before initiating ICIs may provide good local control, pulmonary response, and prolonged prognosis, which can be considered an abscopal effect, for advanced NSCLC. Our analysis found no significant differences in clinical outcomes among different irradiated BoM sites, suggesting that therapeutic benefits may apply broadly. However, due to limited sample size and site heterogeneity, further studies are needed to explore site-specific effects and optimize treatment. While our results are promising, the retrospective nature and heterogeneity in RT protocols preclude definitive clinical recommendations. Further prospective studies are needed to determine the optimal timing, dosage, fractionation, and the role of irradiated sites to establish standardized treatment protocols for clinical practice.
This study had several limitations. First, it was a retrospective analysis conducted at a single center without randomization or a control group, which may have introduced selection bias and limited generalizability. Second, the RT-BoM group included a small number of patients (n=33), and RT regimens varied in dose, fractionation, and treatment site, limiting the evaluation of specific RT parameters. Third, although a possible abscopal effect was suggested, its underlying mechanisms remain unclear. Notably, we did not assess changes in the tumor immune microenvironment or PD-L1 expression, which limits interpretation of the immunological response. Further prospective, multi-center studies, including randomized controlled trials with standardized RT protocols and immune profiling, are necessary to validate and expand upon these findings.
In conclusion, in ICI treatment of NSCLC with BoMs, irradiation of BoMs was associated with improved lung lesion response and prolonged prognosis, suggesting a possible abscopal effect. In addition to local control of BoMs, systemic clinical benefits were observed. However, due to the limitations of this study, including its retrospective single-center design, small sample size, and heterogeneity in RT protocols, these findings should be interpreted with caution. Further prospective, multi-center studies and mechanistic investigations are warranted to confirm and better understand the observed effects and to develop an optimized immunoradiotherapeutic strategy.
Acknowledgements
Not applicable.
Availability of data and materials
The data generated in the present study are not publicly available due to privacy or ethical restrictions but may be requested from the corresponding author.
Authors' contributions
YA, KH, MO, IM, SY and SD conceptualized the study. YA, KH, SM, YT, MO, IM and SY developed the methodology. YA performed the formal analysis. YA, KH, SM, YT, MO, IM and SY conducted the investigation and data acquisition. KH, SY and SD confirm the authenticity of all the raw data. YA wrote the original draft. KH, MO, IM, SY and SD performed review and editing. KH and SD supervised the study. All authors have read and approved the final version of the manuscript.
Ethics approval and consent to participate
The present study was approved by the Medical Ethics Committee of Kanazawa University (no. 3339-1; Kanazawa, Japan). The requirement for written informed consent was waived due to the retrospective design. Instead, consent was obtained via an opt-out method approved by the ethics committee, with study information provided publicly to allow patients to decline participation.
Patient consent for publication
Written informed consent for publication was not required for the present study because all data were fully anonymized and contained no identifiable patient information.
Competing interests
The authors declare that they have no competing interests.
AbbreviationsBoM
bone metastasis
ICI
immune checkpoint inhibitor
irAE
immune-related adverse event
NSCLC
non-small cell lung cancer
OS
overall survival
PD-1
programmed cell death protein 1
PD-L1
programmed cell death ligand 1
PFS
progression-free survival
RT
radiotherapy
SRE
skeletal-related event
TPS
tumor proportion score
ReferencesHerbstRSBaasPKimDWFelipEPérez-GraciaJLHanJYMolinaJKimJHArvisCDAhnMJPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trialLancet38715401550201610.1016/S0140-6736(15)01281-726712084BrahmerJReckampKLBaasPCrinòLEberhardtWEPoddubskayaEAntoniaSPluzanskiAVokesEEHolgadoENivolumab versus docetaxel in advanced squamous-cell non-Small-Cell lung cancerN Engl J Med373123135201510.1056/NEJMoa150462726028407BorghaeiHPaz-AresLHornLSpigelDRSteinsMReadyNEChowLQVokesEEFelipEHolgadoENivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancerN Engl J Med37316271639201510.1056/NEJMoa150764326412456ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAGottfriedMPeledNTafreshiACuffeSPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med37518231833201610.1056/NEJMoa160677427718847RittmeyerABarlesiFWaterkampDParkKCiardielloFVon PawelJGadgeelSMHidaTKowalskiDMDolsMCAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trialLancet389255265201710.1016/S0140-6736(16)32517-X27979383MokTSKWuYLKudabaIKowalskiDMChoBCTurnaHZCastroGSrimuninnimitVLaktionovKKBondarenkoIPembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, Open-label, controlled, phase 3 trialLancet39318191830201910.1016/S0140-6736(18)32409-730955977AsanoYYamamotoNDemuraSHayashiKTakeuchiAKatoSMiwaSIgarashiKHiguchiTYonezawaHThe therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancerFront Oncol12871675202210.3389/fonc.2022.87167535433422AsanoYYamamotoNDemuraSHayashiKTakeuchiAKatoSMiwaSIgarashiKHiguchiTTaniguchiYCombination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastasesLung Cancer193107858202410.1016/j.lungcan.2024.10785838901176AsanoYYamamotoNDemuraSTakeuchiAKatoSMiwaSOkudaMMatsumotoIYanoSDemuraSSerum inflammatory dynamics as novel biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer with bone metastasesAnticancer Res4444934503202410.21873/anticanres.1727839348990AsanoYYamamotoNHayashiKHayashiKTakeuchiAKatoSMiwaSIgarashiKHiguchiTTaniguchiYNovel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasisCancer Med121242512437202310.1002/cam4.595237076988AsanoYHayashiKTakeuchiAKatoSMiwaSTaniguchiYOkudaMMatsumotoIYanoSDemuraSCombining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastasesInt Immunopharmacol136112276202410.1016/j.intimp.2024.11227638820958KawachiHTamiyaMTamiyaAIshiiSHiranoKMatsumotoHFukudaYYokoyamaTKominamiRFujimotoDAssociation between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: A retrospective multicenter cohort studyInvest New Drugs38211218202010.1007/s10637-019-00882-531784866LandiLD'IncàFGelibterAChiariRGrossiFDelmonteAPassaroASignorelliDGelsominoFGalettaDBone metastases and immunotherapy in patients with advanced non-small-cell lung cancerJ Immunother Cancer7316201910.1186/s40425-019-0793-831752994YinMGuanSDingXZhuangRSunZWangTZhengJLiLGaoXWeiHConstruction and validation of a novel web-based nomogram for patients with lung cancer with bone metastasis: A real-world analysis based on the SEER databaseFront Oncol121075217202210.3389/fonc.2022.107521736568214DemariaSFormentiSCThe abscopal effect 67 years later: From a side story to center stageBr J Radiol9320200042202010.1259/bjr.2020004232101479WalleTMartinez MongeRCerwenkaAAjonaDMeleroILecandaFRadiation effects on antitumor immune responses: Current perspectives and challengesTher Adv Med Oncol101758834017742575201810.1177/175883401774257529383033MoritaYSaijoANokiharaHMitsuhashiAYonedaHOtsukaKOginoHBandoYNishiokaYRadiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancerThorac Cancer1310791082202210.1111/1759-7714.1433035064748BangASchoenfeldJDImmunotherapy and radiotherapy for metastatic cancersAnn Palliat Med8312325201910.21037/apm.2018.07.1030180743XingDSivaSHannaGGThe abscopal effect of stereotactic radiotherapy and immunotherapy: Fool's Gold or El Dorado?Clin Oncol31432443201910.1016/j.clon.2019.04.00631005381FioricaFTebanoUGabbaniMPerroneMMissiroliSBerrettaMGiulianiJBonettiARemoAPigozziEBeyond abscopal effect: A meta-analysis of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancerCancers (Basel)132352202110.3390/cancers1310235234068133ZhengYLiuXLiNZhaoASunZWangMLuoJRadiotherapy combined with immunotherapy could improve the immune infiltration of melanoma in mice and enhance the abscopal effectRadiat Oncol J41129139202310.3857/roj.2023.0018537403355WeiJMontalvo-OrtizWYuLKrascoAEbsteinSCortezCLowyIMurphyAJSleemanMASkokosDSequence of alphaPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responsesSci Immunol6eabg0117202110.1126/sciimmunol.abg011733837124ParkBYeeCLeeKMThe effect of radiation on the immune response to cancersInt J Mol Sci15927943201410.3390/ijms1501092724434638MondiniMLevyAMezianiLMilliatFDeutschERadiotherapy-immunotherapy combinations-Perspectives and challengesMol Oncol1415291537202010.1002/1878-0261.1265832112478AntoniaSJVillegasADanielDVicenteDMurakamiSHuiRKurataTChiapporiALeeKHDe WitMOverall survival with durvalumab after chemoradiotherapy in stage III NSCLCN Engl J Med37923422350201810.1056/NEJMoa180969730280658GrayJEVillegasADanielDVicenteDMurakamiSHuiRKurataTChiapporiALeeKHChoBCThree-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFICJ Thorac Oncol15288293202010.1016/j.jtho.2019.10.00231622733TheelenWSMEPeulenHMULalezariFvan der NoortVDe VriesJFAertsJGDumoulinDWBahceINiemeijerALDe LangenAJEffect of pembrolizumab after stereotactic Body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trialJAMA Oncol512761282201910.1001/jamaoncol.2019.147831294749ShaverdianNLisbergAEBornazyanKVeruttipongDGoldmanJWFormentiSCGaronEBLeePPrevious radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of Non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trialLancet Oncol18895903201710.1016/S1470-2045(17)30380-728551359BatesJEMorrisCGMilanoMTYeungARHoppeBSImmunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer DatabaseRadiother Oncol1387579201910.1016/j.radonc.2019.06.00431252297FosterCCSherDJRusthovenCGVermaVSpiottoMTWeichselbaumRRKoshyMOverall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: A National Cancer Database analysisRadiat Oncol1418201910.1186/s13014-019-1222-330691492WelshJMenonHChenDVermaVTangCAltanMHessKDe GrootPNguyenQNVargheseRPembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I/II trialJ Immunother Cancer8e001001202010.1136/jitc-2020-00100133051340TheelenWSMEChenDVermaVHobbsBPPeulenHMAertsJGBahceINiemeijerALChangJYde GrootPMPembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trialsLancet Respir Med9467475202110.1016/S2213-2600(20)30391-X33096027LiuZXuTChangPFuWWeiJXiaCWangQLiMPuXHuangFEfficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysisFront Pharmacol141064227202310.3389/fphar.2023.106422736762107TomacielloMConteMMontinaroFRSabatiniACunicellaGDi GiammarcoFTiniPGravinaGLCortesiEMinnitiGAbscopal effect on bone metastases from solid tumors: A systematic review and retrospective analysis of challenge within a challengeBiomedicines111157202310.3390/biomedicines1104115737189775Rodríguez PláMDualde BeltránDFerrer AlbiachEImmune checkpoints inhibitors and SRS/SBRT synergy in metastatic non-small-cell lung cancer and melanoma: A systematic reviewInt J Mol Sci2211621202110.3390/ijms22211162134769050GengYZhangQFengSLiCWangLZhaoXYangZLiZLuoHLiuRSafety and efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysisCancer Med1012221239202110.1002/cam4.371833465302KanCVargasGLe PapeFClézardinPCancer cell colonisation in the bone microenvironmentInt J Mol Sci171674201610.3390/ijms1710167427782035SantiniDBarniSIntagliataSFalconeAFerraùFGalettaDMoscettiLLa VerdeNIbrahimTPetrelliFNatural history of non-small-cell lung cancer with bone metastasesSci Rep518670201510.1038/srep1867026690845LutzSBalboniTJonesJLoSPetitJRichSEWongRHahnCPalliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based GuidelinePract Radiat Oncol7412201710.1016/j.prro.2016.08.00127663933MakitaKHamamotoYKanzakiHKataokaMYamamotoSNagasakiKIshikawaHTakataNTsuruokaSUwatsuKLocal control of bone metastases treated with external beam radiotherapy in recent years: A multicenter retrospective studyRadiat Oncol16225202110.1186/s13014-021-01940-034801042LeVasseurNClemonsMHuttonBShorrRJacobsCBone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trialsCancer Treat Rev50183193201610.1016/j.ctrv.2016.09.01327716496FacilissimoINatoliGGaspariFComandoneTBongiovanniDGolliniPProvenzaCComandoneAThe role of bone radiotherapy during immune checkpoint inhibitors treatment of non-small-cell lung cancer: A single-institution experienceTher Adv Med Oncol1717588359251332451202510.1177/1758835925133245140336632JayathilakaBMianFFranchiniFAu-YeungGIJzermanMCancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: A systematic reviewBr J Cancer1325157202510.1038/s41416-024-02920-339489880Suazo-ZepedaEBokernMVinkePCHiltermannTJDe BockGHSidorenkovGRisk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: A systematic review and meta-analysisCancer Immunol Immunother7030693080202110.1007/s00262-021-02996-334195862DangTOOgunniyiABarbeeMSDrilonAPembrolizumab for the treatment of PD-L1 positive advanced or metastatic Non-small cell lung cancerExpert Rev Anticancer Ther161320201610.1586/14737140.2016.112362626588948
(A) Overall survival and (B) progression-free survival in the RT-BoM and non-RT-BoM groups. BoM, bone metastasis; mOS, median overall survival; mPFS, median progression-free survival; RT, radiotherapy.
Figure 1. (A) Overall survival and (B) progression–free survival in the RT–BoM and non–RT–BoM groups. BoM, bone metastasis; mOS, median overall survival; mPFS, median progression–free survival; RT, ra...